Oral Versus Intravenous Antibiotics for the Treatment of Pleural Space Infection: a Randomized Controlled Pilot Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must meet our study definition of pleural space infection
- Age > or = 18 years old
- Life expectancy > 1 year
- Received intravenous or oral antibiotics for = or < 7 d from surgical intervention or received a total of = or < 7 d of antibiotics if no intervention performed
Exclusion Criteria:
- S. aureus bacteremia or endocarditis in the last 1 month
- Another concomitant infection requiring prolonged IV antibiotics
- Esophageal rupture or malignant pleural effusion
- Septic shock or systemic features requiring IV antibiotics
- Mycobacterial, fungal or parasitic pleural space infection
- No oral antibiotic options available
- Unlikely to comply with therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Intravenous therapy
Intravenous antibiotics administered for pleural space infection
|
Oral versus intravenous therapy
|
|
Active Comparator: Oral therapy
Oral antibiotics administered for pleural space infection
|
Oral versus intravenous therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Enrollment feasibility
Time Frame: 3 months
|
Proportion of eligible participants screened that are randomized within 5 days of initial intravenous antibiotic exposure
|
3 months
|
|
Completion feasibility
Time Frame: 3 months
|
Proportion of participants with follow-up at 4 weeks either through a clinic visit or phone call
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment failure
Time Frame: 3 months
|
Treatment failure at the 3-month clinical visit or phone conversation, defined as any of: (i) return to the emergency department for new fever, shortness of breath or progressive hypoxia OR (ii) radiological progression of empyema or development of a new abscess OR (iii) mortality related to pleural space infection.
Treatment failure must be agreed upon by the majority of the adjudication committee.
|
3 months
|
|
Mortality
Time Frame: 3 months
|
All-cause mortality at 3 months
|
3 months
|
|
Antibiotic duration
Time Frame: 3 months
|
Duration of antibiotics with start date as the date of randomization
|
3 months
|
|
Hospitalization duration
Time Frame: 3 months
|
Duration of hospitalization
|
3 months
|
|
Stopping antibiotics
Time Frame: 3 months
|
Early termination of antibiotics due to patient intolerance, patient preference or any other reason.
|
3 months
|
|
IV line complications
Time Frame: 3 months
|
Infection, thrombosis or new line placement for IV catheter-related issues.
|
3 months
|
|
C. difficile
Time Frame: 3 months
|
Clostridium difficile associated diarrhea as per the accepted PIDAC definition
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PSI Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.